Abstract | BACKGROUND:
Exportin 1 (XPO1, also known as CRM1), is a chaperone protein responsible for the export of over 200 target proteins out of the nucleus. The expression and activity of XPO1 is upregulated in several human cancers and its expression is also linked to the development of chemotherapy resistance. Recent studies using both human and murine cancer cell lines have demonstrated that XPO1 is a relevant target for therapeutic intervention. The present study sought to characterize the biologic activity of an orally bioavailable selective inhibitor of nuclear export (SINE), KPT-335, against canine melanoma cell lines as a prelude to future clinical trials in dogs with melanoma. RESULTS: CONCLUSIONS:
|
Authors | Megan N Breit, William C Kisseberth, Misty D Bear, Yosef Landesman, Trinayan Kashyap, Dilara McCauley, Michael G Kauffman, Sharon Shacham, Cheryl A London |
Journal | BMC veterinary research
(BMC Vet Res)
Vol. 10
Pg. 160
(Jul 15 2014)
ISSN: 1746-6148 [Electronic] England |
PMID | 25022346
(Publication Type: Journal Article)
|
Chemical References |
- Acrylamides
- Antineoplastic Agents
- Cyclin-Dependent Kinase Inhibitor p21
- Hydrazines
- Karyopherins
- Receptors, Cytoplasmic and Nuclear
- Tumor Suppressor Protein p53
- exportin 1 protein
- verdinexor
|
Topics |
- Acrylamides
(administration & dosage, pharmacology)
- Animals
- Antineoplastic Agents
(pharmacology)
- Apoptosis
- Biological Availability
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Cyclin-Dependent Kinase Inhibitor p21
(genetics, metabolism)
- Dogs
- Dose-Response Relationship, Drug
- Gene Expression Regulation, Neoplastic
(drug effects)
- Hydrazines
(administration & dosage, pharmacology)
- Karyopherins
(genetics, metabolism)
- Melanoma
- Receptors, Cytoplasmic and Nuclear
(genetics, metabolism)
- Tumor Suppressor Protein p53
(genetics, metabolism)
|